The short version of clinical endpoint fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, he has joined S.P.D.'s Earth unit and married Jasmine, with whom they have a son named Taiga. Hikaru Hiwatari is portrayed by Yuto Uemura (上村 祐翔, Uemura Yūto). Zamuzan Myra (ザムザ星人マイラ, Zamuza Seijin Maira): A young woman from Planet Zamuza who was the subject of a stakeout conducted by the Dekarangers due to her ex-boyfriend, an Alienizer named Sheik, having recently escaped from prison. However, Ban becomes enamored by her and goes undercover as her apartment building's plumber to socialize with her. After Sheik attacks Myra and the Dekarangers delete him, Myra loses respect for Ban for lying to her, but chooses to remain friends with him since he kept his promise to protect her. Myra is portrayed by Nana Nakamoto (中本 奈奈, Nakamoto Nana). Ocarnan Amy (オカーナ星人エイミー, Okāna Seijin Eimī): A giant alien baby from planet Ocarna who possesses currently uncontrollable size-changing capabilities limited by a special pacifier and shockwave-inducing cries. After Amy's cradle pod lands on Earth, Umeko is assigned to protect her until the former's parents can come for her. Agent Abrella sends an Igaroid to pilot a Kaijuki called Devil Capture 3 (デビルキャプチャー3, Debiru Kyapuchā Surī) and capture Amy, but Umeko destroys them with Dekaranger Robo before Amy's parents arrive and take their daughter back. Amy is voiced by Sara Nakayama (中山 さら, Nakayama Sara).
Large anti-Trump protests, named "Hands off Greenland", took place across Greenland and Denmark on 17 January to protest against Trump's threats against Greenland. The solidarity protests are organised by Greenlandic associations in Copenhagen, Aarhus, Aalborg, Odense and Nuuk. Uagut, an association of Greenlanders in Denmark, said the aim of the protests is to send a message of respect for Greenland's democracy and fundamental human rights. In Copenhagen, thousands of Greenlanders and Danes filled City Hall Square. Protesters chanted "Greenland is not for sale" and "Kalaallit Nunaat" and marched to the US embassy in Copenhagen in solidarity with Greenlanders. The slogan "Make America Go Away" soared in popularity in response to the protests, becoming a symbol of anti-Trump defiance. In addition to earlier protests, on 21 May 2026, after the opening of a new United States consulate in Nuuk, hundreds of people protested in the capital of Greenland. Demonstrators chanted slogans such as "Greenland for Greenlanders", opposing the expansion of American diplomatic presence in the autonomous territory.
Emanuel Gil-Av (Zimkin) (Hebrew: עמנואל גיל-אב; 7 August 1916 – 24 March 1996) was an Israeli chemist. The main emphasis of his work constituted chiral chromatography for the analytical separation of enantiomers.
Attenuated total reflectance (ATR) is one accessory of FTIR spectrophotometer to measure surface properties of solid or thin film samples rather than their bulk properties. Generally, ATR has a penetration depth of around 1 or 2 micrometers depending on sample conditions.
Actinium-225 decays exclusively by alpha emission. It is part of the neptunium series, for it arises as a decay product of neptunium-237 and its daughters such as uranium-233 and thorium-229. It is the last nuclide in the chain with a half-life over a day until the penultimate product, bismuth-209 (half-life 2.01×1019 years). The final decay product of 225Ac is stable 205Tl. As a member of the neptunium series, it does not occur in nature except as a product of trace quantities of 237Np and its daughters formed by neutron capture reactions on primordial 232Th and (n,2n) reactions on 238U. It is much rarer than 227Ac and 228Ac, which respectively occur in the decay chains of uranium-235 and thorium-232. Its abundance was estimated as less than 1.1×10−19 relative to 232Th and around 9.9×10−16 relative to 230Th in secular equilibrium.
Sources: en.wikipedia.org
=== Opposition === On March 13, 2012, over 100 environmental and civil society groups, including Friends of the Earth, the International Center for Technology Assessment, and the ETC Group, issued the manifesto The Principles for the Oversight of Synthetic Biology. This manifesto calls for a worldwide moratorium on the release and commercial use of synthetic organisms until more robust regulations and rigorous biosafety measures are established. The groups specifically call for an outright ban on the use of synthetic biology on the human genome or human microbiome. Richard Lewontin wrote that some of the safety tenets for oversight discussed in The Principles for the Oversight of Synthetic Biology are reasonable, but that the main problem with the recommendations in the manifesto is that "the public at large lacks the ability to enforce any meaningful realization of those recommendations".
Charlotte Dacre (1771 or 1772 – 7 November 1825) English author of Gothic novels; wrote under the pseudonym "Rosa Matilda" to confuse her critics; her work was admired by some of the literary giants of her day and her novels influenced Percy Bysshe Shelley, who thought highly of her style and creative skills. Ellen Dahrendorf, Baroness Dahrendorf (née Ellen Joan Krug), author, historian, translator of Russian political works; former wife (1980–2004) of the late German/British academic and politician Ralf Dahrendorf; has served on the boards of Article 19, the Jewish Institute for Policy Research; has been chair of British branch of the New Israel Fund; was co-founder of the Working Group on the Internment of Dissidents in Psychiatric Hospitals; is a signatory of the Independent Jewish Voices declaration, which is critical of Israeli policies towards the Palestinians. Aviva Dautch (born 5 May 1978) poet, academic, curator and magazine publisher, of Eastern European ancestry; writer in residence at the British Museum, the Jewish Museum London and the Separated Child Foundation and is resident expert on BBC Radio 4's poetry series On Form; English co-translator for Afghan refugee poet and BBC World Service journalist Suhrab Sirat; has written articles, and curated exhibitions and events for arts organisations including the Bethlem Museum of the Mind, The British Library, The Royal Academy of Arts and Tara Arts;lectures internationally on Jewish arts and culture. In 2020 she was appointed executive director of Jewish Renaissance magazine.
== Theranos == In May 2015, Diamandis performed a deep investigation into claims of health technology company Theranos and concluded in a report that "most of the company's claims are exaggerated." This insight from Diamandis triggered John Carreyrou to further investigate the claims that had been made by Theranos. At the time, Theranos was widely considered a reliable and functional analysis company.
The idea that life originated from non-living matter in slow stages appeared in Herbert Spencer's 1864–1867 book Principles of Biology, and in William Turner Thiselton-Dyer's 1879 paper "On spontaneous generation and evolution". On 1 February 1871 Charles Darwin wrote about these publications to Joseph Hooker, and set out his own speculation that the original spark of life may have been in a "warm little pond, with all sorts of ammonia and phosphoric salts,—light, heat, electricity &c present, that a protein compound was chemically formed". Darwin explained that "at the present day such matter would be instantly devoured or absorbed, which would not have been the case before living creatures were formed." Alexander Oparin in 1924 and J. B. S. Haldane in 1929 proposed that the earliest cells slowly self-organized from a primordial soup, the Oparin–Haldane hypothesis. Haldane suggested that the Earth's prebiotic oceans consisted of a "hot dilute soup" in which organic compounds could have formed. J. D. Bernal showed that such mechanisms could form most of the necessary molecules for life from inorganic precursors. In 1967, he suggested three "stages": the origin of biological monomers; the origin of biological polymers; and the evolution from molecules to cells.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.